Skip to content

Cognitive Screening in Lung Cancer Patients

Cognitive Screening in Lung Cancer Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06727370
Enrollment
200
Registered
2024-12-10
Start date
2024-01-10
Completion date
2025-12-31
Last updated
2024-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Disease, NSCLC (Non-small Cell Lung Cancer), SCLC

Keywords

lung cancer, nsclc, sclc, cognitive

Brief summary

This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.

Interventions

None listed

Sponsors

European Institute of Oncology
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Small-cell and non-small-cell lung cancer (stage I, II, III, IV) * Age ≥ 18 years * Patients able to speak and read the local language(s) fluently * Acceptance and signature of informed consent

Exclusion criteria

* Age ≥ 70 * Presence of brain metastases * Patients with concomitant neurological or psychiatric disorders. * Patients undergoing brain radiotherapy * Previous diagnosis of lung cancer

Design outcomes

Primary

MeasureTime frameDescription
cognitive impairmentFrom baseline to 12 monthsIt will be the presence of cognitive impairment through the administration of a comprehensive neuropsychological assessment.Patient will complete cognitive evaluation which includes:the Montreal Cognitive Assessment and the Mini-Mental State Examination to assess global cognitive functioning;the Frontal Assessment Battery,the Stroop test color and word test ,and the Verbal Fluency Test for the evaluation of executive function;the Ray Auditory Verbal Learning Test for learning and memory;the forward and backward Digit Span and the Corsi Block-tapping Test for working memory;and the Trail Making Test A & B and the Symbol Digit Modalities Test for attention. Classification will be obtained adopting the criteria proposed by the International Cognition and Cancer Task Force,a test score of 2 SDs or more below the test-specific reference cohort on at least 1 test of a cognitive domain.All test scores were transformed into z-scores to allow the comparison between different measures.

Secondary

MeasureTime frameDescription
Risk factors on the cognitive profile of lung cancer patientsFrom baseline to 12 monthsThis study will assess the influence of different risk factors on the cognitive profile of lung cancer patients. It will examine the role of psychological symptoms through different self-reported questionnaire: the Functional Assessment of Cancer Therapy - cognition will be administered to assess perceived cognitive impairment, the Beck Depression Inventory II to measure the presence of depressive symptoms, the State-Trait Anxiety Inventory to investigate both state anxiety and trait anxiety, the EORTC-Quality of Life of cancer patient to assess the quality of life and, finally, the Pittsburgh Sleep Quality Index to evaluate sleep quality and disturbances sleep patterns. Finally, the Cognitive Reserve Index questionnaire will be administered to obtain the cognitive reserve level of each patient, and the smoking information obtained through an interview.All the questionnaire scores were transformed into z-scores to allow the comparison between different measures.

Countries

Italy

Contacts

Primary ContactGabriella Pravettoni
gabriella.pravettoni@ieo.it+39025489731
Backup ContactLorenzo Conti
+390257489731

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026